233 related articles for article (PubMed ID: 23160468)
1. WT1-specific T-cell responses in high-risk multiple myeloma patients undergoing allogeneic T cell-depleted hematopoietic stem cell transplantation and donor lymphocyte infusions.
Tyler EM; Jungbluth AA; O'Reilly RJ; Koehne G
Blood; 2013 Jan; 121(2):308-17. PubMed ID: 23160468
[TBL] [Abstract][Full Text] [Related]
2. Graft-versus-leukemia effect with a WT1-specific T-cell response induced by azacitidine and donor lymphocyte infusions after allogeneic hematopoietic stem cell transplantation.
Ishikawa T; Fujii N; Imada M; Aoe M; Meguri Y; Inomata T; Nakashima H; Fujii K; Yoshida S; Nishimori H; Matsuoka KI; Kondo E; Maeda Y; Tanimoto M
Cytotherapy; 2017 Apr; 19(4):514-520. PubMed ID: 28139337
[TBL] [Abstract][Full Text] [Related]
3. Towards effective and safe immunotherapy after allogeneic stem cell transplantation: identification of hematopoietic-specific minor histocompatibility antigen UTA2-1.
Oostvogels R; Minnema MC; van Elk M; Spaapen RM; te Raa GD; Giovannone B; Buijs A; van Baarle D; Kater AP; Griffioen M; Spierings E; Lokhorst HM; Mutis T
Leukemia; 2013 Mar; 27(3):642-9. PubMed ID: 23079962
[TBL] [Abstract][Full Text] [Related]
4. Graft-versus-leukemia effects of Wilms' tumor 1 protein-specific cytotoxic T lymphocytes in patients with chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
Wang ZD; Li D; Huang XJ
Chin Med J (Engl); 2010 Apr; 123(7):912-6. PubMed ID: 20497687
[TBL] [Abstract][Full Text] [Related]
5. Generation of multi-leukemia antigen-specific T cells to enhance the graft-versus-leukemia effect after allogeneic stem cell transplant.
Weber G; Gerdemann U; Caruana I; Savoldo B; Hensel NF; Rabin KR; Shpall EJ; Melenhorst JJ; Leen AM; Barrett AJ; Bollard CM
Leukemia; 2013 Jul; 27(7):1538-47. PubMed ID: 23528871
[TBL] [Abstract][Full Text] [Related]
6. Monitoring of WT1-specific cytotoxic T lymphocytes after allogeneic hematopoietic stem cell transplantation.
Morita Y; Heike Y; Kawakami M; Miura O; Nakatsuka S; Ebisawa M; Mori S; Tanosaki R; Fukuda T; Kim SW; Tobinai K; Takaue Y
Int J Cancer; 2006 Sep; 119(6):1360-7. PubMed ID: 16596644
[TBL] [Abstract][Full Text] [Related]
7. T-cell--depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect.
Alyea E; Weller E; Schlossman R; Canning C; Webb I; Doss D; Mauch P; Marcus K; Fisher D; Freeman A; Parikh B; Gribben J; Soiffer R; Ritz J; Anderson K
Blood; 2001 Aug; 98(4):934-9. PubMed ID: 11493435
[TBL] [Abstract][Full Text] [Related]
8. The emergence of WT1-specific T-cell responses following allogeneic T cell-depleted hematopoietic stem cell transplantation and low-dose donor lymphocyte infusions is associated with a graft-vs.- myeloma effect.
Tyler EM; Koehne G
Oncoimmunology; 2013 Jul; 2(7):e24963. PubMed ID: 24073375
[TBL] [Abstract][Full Text] [Related]
9. Immune responses to WT1 in patients with AML or MDS after chemotherapy and allogeneic stem cell transplantation.
Casalegno-Garduño R; Schmitt A; Spitschak A; Greiner J; Wang L; Hilgendorf I; Hirt C; Ho AD; Freund M; Schmitt M
Int J Cancer; 2016 Apr; 138(7):1792-801. PubMed ID: 26519872
[TBL] [Abstract][Full Text] [Related]
10. Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients.
Chapuis AG; Ragnarsson GB; Nguyen HN; Chaney CN; Pufnock JS; Schmitt TM; Duerkopp N; Roberts IM; Pogosov GL; Ho WY; Ochsenreither S; Wölfl M; Bar M; Radich JP; Yee C; Greenberg PD
Sci Transl Med; 2013 Feb; 5(174):174ra27. PubMed ID: 23447018
[TBL] [Abstract][Full Text] [Related]
11. Generation of donor-derived Wilms tumor antigen 1-specific cytotoxic T lymphocytes with potent anti-leukemia activity for somatic cell therapy in children given haploidentical stem cell transplantation: a feasibility pre-clinical study.
Ferulli F; Tanzi M; Turin I; Montini E; Rosti V; Acquafredda G; Lisini D; Compagno F; Boghen S; Licari A; Marseglia G; Zecca M; Montagna D
Cytotherapy; 2019 Sep; 21(9):958-972. PubMed ID: 31279696
[TBL] [Abstract][Full Text] [Related]
12. Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant.
Alyea EP; Soiffer RJ; Canning C; Neuberg D; Schlossman R; Pickett C; Collins H; Wang Y; Anderson KC; Ritz J
Blood; 1998 May; 91(10):3671-80. PubMed ID: 9573003
[TBL] [Abstract][Full Text] [Related]
13. Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity.
Peggs KS; Mackinnon S; Williams CD; D'Sa S; Thuraisundaram D; Kyriakou C; Morris EC; Hale G; Waldmann H; Linch DC; Goldstone AH; Yong K
Biol Blood Marrow Transplant; 2003 Apr; 9(4):257-65. PubMed ID: 12720218
[TBL] [Abstract][Full Text] [Related]
14. Long-term follow-up of T cell-depleted allogeneic bone marrow transplantation in refractory multiple myeloma: importance of allogeneic T cells.
Huff CA; Fuchs EJ; Noga SJ; O'Donnell PV; Ambinder RF; Diehl L; Borrello I; Vogelsang GB; Miller CB; Flinn IA; Brodsky RA; Marcellus D; Jones RJ
Biol Blood Marrow Transplant; 2003 May; 9(5):312-9. PubMed ID: 12766881
[TBL] [Abstract][Full Text] [Related]
15. Different recovery patterns of CMV-specific and WT1-specific T cells in patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation: Impact of CMV infection and leukemia relapse.
Luo XH; Poiret T; Liu Z; Meng Q; Nagchowdhury A; Ljungman P
Front Immunol; 2022; 13():1027593. PubMed ID: 36824620
[TBL] [Abstract][Full Text] [Related]
16. A phase I study of CD25/regulatory T-cell-depleted donor lymphocyte infusion for relapse after allogeneic stem cell transplantation.
Nikiforow S; Kim HT; Daley H; Reynolds C; Jones KT; Armand P; Ho VT; Alyea EP; Cutler CS; Ritz J; Antin JH; Soiffer RJ; Koreth J
Haematologica; 2016 Oct; 101(10):1251-1259. PubMed ID: 27354021
[TBL] [Abstract][Full Text] [Related]
17. Cancer-testis antigen 7 expression and immune responses following allogeneic stem cell transplantation for multiple myeloma.
Tyler EM; Jungbluth AA; Gnjatic S; O'Reilly RJ; Koehne G
Cancer Immunol Res; 2014 Jun; 2(6):547-58. PubMed ID: 24894092
[TBL] [Abstract][Full Text] [Related]
18. Induction of Immune Response after Allogeneic Wilms' Tumor 1 Dendritic Cell Vaccination and Donor Lymphocyte Infusion in Patients with Hematologic Malignancies and Post-Transplantation Relapse.
Shah NN; Loeb DM; Khuu H; Stroncek D; Ariyo T; Raffeld M; Delbrook C; Mackall CL; Wayne AS; Fry TJ
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2149-2154. PubMed ID: 27634018
[TBL] [Abstract][Full Text] [Related]
19. Wilms Tumor 1 Expression and Pre-emptive Immunotherapy in Patients with Acute Myeloid Leukemia Undergoing an Allogeneic Hemopoietic Stem Cell Transplantation.
Di Grazia C; Pozzi S; Geroldi S; Grasso R; Miglino M; Colombo N; Tedone E; Luchetti S; Lamparelli T; Gualandi F; Ibatici A; Bregante S; Van Lint MT; Raiola AM; Dominietto A; Varaldo R; Galaverna F; Ghiso A; Sica S; Bacigalupo A
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1242-1246. PubMed ID: 26970379
[TBL] [Abstract][Full Text] [Related]
20. Donor Lymphocyte Infusions After Allogeneic Transplantation: A Single-Center Experience.
Kerbage F; Sakr R; Lapierre V; Alexandrova K; Coman T; Leroux S; Lucas N; Pilorge S; Solary E; Bourhis JH; Castilla-Llorente C
Clin Lymphoma Myeloma Leuk; 2020 Apr; 20(4):209-211. PubMed ID: 32019730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
